GlassScriptPhysician profile
Rodgers Long Eckhart
NPI 1063612638
$2,667.43
in general payments reported to CMS, 2019-2025
19 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $68.25 · 2021: $145 · 2022: $470 · 2023: $557 · 2024: $262 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447 · Entertainment: $37.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.05 |
| Entertainment | $37.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $643.77 | 2019-2025 | Clareon, Argos, Ngenuity |
| Sun Pharmaceutical Industries INC. | $564.02 | 2019-2025 | Cequa |
| Abbvie INC. | $244.45 | 2022-2025 | Lumigan, Alphagan P |
| Rxsight INC | $181.84 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $178.94 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $161.83 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Biotissue Holdings INC. | $140.71 | 2022-2024 | |
| Allergan, INC. | $130.21 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.53 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $58.53 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $47.83 | 2019 | |
| Oyster Point Pharma, INC. | $46.98 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $38.43 | 2019-2022 | |
| Optos, INC. | $37.23 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eyepoint US, INC. | $23.93 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.28 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $21.34 | 2024 | Tecnis Iol |
| Tearlab Corp | $19.41 | 2021 | |
| Shire North American Group INC | $17.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodgers Eckhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.